No abstract available
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Golgi Matrix Proteins / genetics*
-
Humans
-
In Situ Hybridization, Fluorescence
-
Janus Kinase 2 / genetics*
-
Karyotyping
-
Male
-
Molecular Targeted Therapy
-
Nitriles
-
Oncogene Proteins, Fusion / genetics*
-
Philadelphia Chromosome
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Pyrimidines
-
Remission Induction
-
Retreatment
-
Treatment Failure
-
Treatment Outcome
-
Vesicular Transport Proteins
Substances
-
GOLGA5 protein, human
-
Golgi Matrix Proteins
-
Nitriles
-
Oncogene Proteins, Fusion
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Vesicular Transport Proteins
-
ruxolitinib
-
JAK2 protein, human
-
Janus Kinase 2